Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $6.63 billion. The enterprise value is $6.33 billion.
Important Dates
The last earnings date was Tuesday, November 4, 2025, before market open.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 66.74 million shares outstanding. The number of shares has increased by 5.39% in one year.
| Current Share Class | 66.74M |
| Shares Outstanding | 66.74M |
| Shares Change (YoY) | +5.39% |
| Shares Change (QoQ) | +4.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 66.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.30 |
| Forward PS | 25.79 |
| PB Ratio | 44.55 |
| P/TBV Ratio | 46.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.75, with a Debt / Equity ratio of 0.38.
| Current Ratio | 4.75 |
| Quick Ratio | 4.31 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.70 |
Financial Efficiency
Return on equity (ROE) is -85.79% and return on invested capital (ROIC) is -34.50%.
| Return on Equity (ROE) | -85.79% |
| Return on Assets (ROA) | -26.74% |
| Return on Invested Capital (ROIC) | -34.50% |
| Return on Capital Employed (ROCE) | -46.25% |
| Revenue Per Employee | $616,021 |
| Profits Per Employee | -$698,625 |
| Employee Count | 283 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.03 |
Taxes
In the past 12 months, RYTM has paid $438,000 in taxes.
| Income Tax | 438,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +65.49% in the last 52 weeks. The beta is 1.96, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +65.49% |
| 50-Day Moving Average | 102.50 |
| 200-Day Moving Average | 77.17 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 677,755 |
Short Selling Information
The latest short interest is 5.23 million, so 7.84% of the outstanding shares have been sold short.
| Short Interest | 5.23M |
| Short Previous Month | 5.57M |
| Short % of Shares Out | 7.84% |
| Short % of Float | 7.89% |
| Short Ratio (days to cover) | 9.40 |
Income Statement
In the last 12 months, RYTM had revenue of $174.33 million and -$197.71 million in losses. Loss per share was -$3.11.
| Revenue | 174.33M |
| Gross Profit | 155.86M |
| Operating Income | -186.21M |
| Pretax Income | -191.89M |
| Net Income | -197.71M |
| EBITDA | -184.76M |
| EBIT | -186.21M |
| Loss Per Share | -$3.11 |
Full Income Statement Balance Sheet
The company has $416.05 million in cash and $113.10 million in debt, giving a net cash position of $302.95 million or $4.54 per share.
| Cash & Cash Equivalents | 416.05M |
| Total Debt | 113.10M |
| Net Cash | 302.95M |
| Net Cash Per Share | $4.54 |
| Equity (Book Value) | 295.68M |
| Book Value Per Share | 2.23 |
| Working Capital | 390.54M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -109.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | -109.13M |
| FCF Per Share | -$1.64 |
Full Cash Flow Statement Margins
Gross margin is 89.40%, with operating and profit margins of -106.81% and -110.32%.
| Gross Margin | 89.40% |
| Operating Margin | -106.81% |
| Pretax Margin | -110.07% |
| Profit Margin | -110.32% |
| EBITDA Margin | -105.98% |
| EBIT Margin | -106.81% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.39% |
| Shareholder Yield | -5.39% |
| Earnings Yield | -2.98% |
| FCF Yield | -1.64% |
Dividend Details Analyst Forecast
The average price target for RYTM is $117.00, which is 17.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $117.00 |
| Price Target Difference | 17.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 63.36% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 8.47 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.47 |
| Piotroski F-Score | 5 |